home All News open_in_new Full Article

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Target enrollment of 100 patients with high-risk, BCG-unresponsive NMIBC with CIS achieved enGene plans to provide an update from LEGEND’s pivotal cohort in 4Q 2025 Biologic License Application (BLA) submission planned for 2H 2026 BOSTON & MONTREAL — enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral gene therapy company, today announced […]


today 1 week ago attach_file Other

attach_file Economics
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Other
attach_file Culture
attach_file Events
attach_file Events
attach_file Sport
attach_file Sport
attach_file Other
attach_file Economics
attach_file Culture
attach_file Events
attach_file Other
attach_file Other
attach_file Events
attach_file Other
attach_file Other


ID: 3785085187
Add Watch Country

arrow_drop_down